New Anti-clotting Drug More Effective than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. (Source: BWH News)
Source: BWH News - March 10, 2013 Category: Hospital Management Source Type: news

New Anti-clotting Drug More Effective than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. (Source: BWH for Journalists)
Source: BWH for Journalists - March 10, 2013 Category: Research Source Type: news

New Anti-clotting Drug More Effective than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. (Source: BWH News)
Source: BWH News - March 10, 2013 Category: Hospital Management Source Type: news

Sanofi says U.S. probing Plavix disclosures to FDA
PARIS (Reuters) - The U.S. Department of Justice (DoJ) is investigating disclosures to the Food & Drug Administration (FDA) about the variable response that certain patients may have to blood-thinner Plavix, Sanofi said in its annual report. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Systematic review and meta-analysis of new oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome
Source: European Heart Journal Area: News Oral vitamin K antagonists have been shown to prevent recurrent ischaemic events after acute coronary syndrome (ACS), both as mono-therapy and in combination with aspirin, but substantially increase bleeding. The potential of new oral anticoagulants as antithrombotic therapy after ACSs has been investigated over the past few years and consistent increases in bleeding and the less consistent reduction in ischaemic events have been reported. The overall benefit-risk profile of adding new oral anticoagulants to antiplatelet treatment after an ACS is unknown.   This meta-anal...
Source: NeLM - Cardiovascular Medicine - March 7, 2013 Category: Cardiology Source Type: news

Tranexamic acid role in coronary bypass surgery
Tranexamic acid balances the increased bleeding risk associated with recent clopidogrel use in patients undergoing on-pump coronary artery bypass grafting, shows a randomized trial. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - March 7, 2013 Category: Cardiology Source Type: news

Aspirin plus drug reduces stroke risk
SAN FRANCISCO, Feb. 27 (UPI) -- Stroke patients or those with a transient ischemic attack who added Plavix to aspirin had less risk of second stroke, U.S. and Chinese researchers say. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 27, 2013 Category: Consumer Health News Source Type: news

Combined clopidogrel, tranexamic acid improved outcomes in CABG patients
(Source: HemOncToday.com)
Source: HemOncToday.com - February 27, 2013 Category: Cancer & Oncology Source Type: news

WOEST supports clopidogrel only in PCI patients on anticoagulation
Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy. (Source: MedWire News - Thrombosis)
Source: MedWire News - Thrombosis - February 25, 2013 Category: Internal Medicine Source Type: news

WOEST supports clopidogrel only in PCI patients on anticoagulation
Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - February 24, 2013 Category: Cardiology Source Type: news

Expert position paper on use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
Source: Eur Heart J Area: News The European Society of Cardiology NSTEMI and STEMI guidelines and an ACCF/ACG/AHA consensus document recommend treatment with proton pump inhibitors (PPIs) in patients treated with dual antiplatelet treatment (DAPT) during the initial phase of an acute coronary syndrome (ACS), particularly in patients with a history of GI bleeding or peptic ulcer. Several studies have raised concerns that many PPIs, especially omeprazole, might diminish the antiplatelet effects of clopidogrel, most likely through inhibition of CYP2C19 and, consequently, the conversion of clopidogrel into its active metaboli...
Source: NeLM - Cardiovascular Medicine - February 21, 2013 Category: Cardiology Source Type: news

Early switch from prasugrel to clopidogrel may influence outcomes
(Source: HemOncToday.com)
Source: HemOncToday.com - February 20, 2013 Category: Cancer & Oncology Source Type: news

Antiplatelet Switch Still Has Bleeding Risks (CME/CE)
(MedPage Today) -- Switching high-risk patients to clopidogrel (Plavix) can help counteract the low platelet reactivity common with prasugrel (Effient), but doing so has risks of its own, a first-of-its-kind study found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2013 Category: Cardiology Source Type: news